We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.72 | -0.56% | 128.50 | 129.93 | 127.80 | 129.43 | 5,895,709 | 01:00:00 |
From May 2019 to May 2024
By Dave Sebastian
Merck & Co. (MRK) posted higher third-quarter sales, driven by gains in oncology and vaccines sales, that drove adjusted earnings above analysts' expectations.
The pharmaceutical company posted net income of $1.9 billion, or 74 cents a share, compared with $1.95 billion, or 73 cents a share, in the comparable quarter last year. Analysts polled by FactSet were expecting $1.01 a share.
Excluding a $982 million charge for the acquisition of Peloton Therapeutics Inc. and other charges, earnings were $1.51 a share, compared with $1.19 a share a year earlier. Analysts were looking for $1.24 a share.
Sales for the quarter rose to $12.4 billion from $10.79 billion in the prior year. Analysts were looking for $11.67 billion.
Sales of Keytruda, Merck's cancer treatment, rose 62% to $3.07 billion for the quarter. Vaccine sales grew 17% to $2.5 billion, Merck said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
October 29, 2019 07:25 ET (11:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
